Pulmonx (NASDAQ: LUNG) CCO sells for taxes, receives 100,000 RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Pulmonx Corp reported insider transactions by its Chief Commercial Officer, Geoffrey Beran. On March 2, 2026, he sold a total of 7,732 shares of common stock at $1.43 per share in open-market sales to cover tax withholding obligations tied to vesting restricted stock units granted in 2022, 2023, 2024, and 2025.

On the same date, he received a grant of 100,000 restricted stock units, payable solely in Pulmonx common stock, which vest in equal quarterly installments over four years from March 2, 2026. Following these transactions, his direct holdings increased to 465,734 shares of common stock.

Insider Trade Summary

Net Seller: 7,732 shares ($11,057)

Net Sell 5 txns

Insider Rose Geoffrey Beran

Role CHIEF COMMERCIAL OFFICER

Sold 7,732 shs ($11K)

Type	Security	Shares	Price	Value
Sale	Common Stock	835	$1.43	$1K
Sale	Common Stock	2,125	$1.43	$3K
Sale	Common Stock	1,861	$1.43	$3K
Sale	Common Stock	2,911	$1.43	$4K
Grant/Award	Common Stock	100,000	$0.00	--

Holdings After Transaction: Common Stock — 372,631 shares (Direct)

Footnotes (1)

These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025. Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 2, 2026.

Form 4 Insider Transactions: What Each Field Means →

03/04/2026 - 07:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rose Geoffrey Beran

(Last)

(First)

(Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF COMMERCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		S⁽¹⁾		835	D	$1.43	372,631	D
Common Stock	03/02/2026		S⁽²⁾		2,125	D	$1.43	370,506	D
Common Stock	03/02/2026		S⁽³⁾		1,861	D	$1.43	368,645	D
Common Stock	03/02/2026		S⁽⁴⁾		2,911	D	$1.43	365,734	D
Common Stock	03/02/2026		A		100,000⁽⁵⁾	A	$0	465,734	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022.

2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.

3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.

4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.

5. Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 2, 2026.

	/s/ David Aaron Lehman, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Pulmonx (LUNG) report for Geoffrey Beran?

Pulmonx reported that Chief Commercial Officer Geoffrey Beran sold 7,732 common shares and received 100,000 restricted stock units. The sales occurred on March 2, 2026, and were open-market transactions primarily to cover tax withholding related to previously granted restricted stock units.

How many Pulmonx (LUNG) shares did Geoffrey Beran sell and at what price?

Geoffrey Beran sold 7,732 shares of Pulmonx common stock at $1.43 per share. These sales were executed in several open-market transactions on March 2, 2026, specifically to cover tax withholding obligations tied to the vesting of earlier restricted stock unit grants.

Why did Pulmonx CCO Geoffrey Beran sell shares of LUNG stock?

The shares were sold to satisfy tax withholding obligations from vesting restricted stock units. Footnotes state each block of shares corresponded to RSUs granted on March 1, 2022, March 1, 2023, March 1, 2024, and March 3, 2025, rather than discretionary open-market selling.

What restricted stock unit grant did Geoffrey Beran receive from Pulmonx (LUNG)?

On March 2, 2026, Geoffrey Beran received a grant of 100,000 restricted stock units payable solely in Pulmonx common stock. These RSUs vest in equal quarterly installments over four years from the grant date, creating a long-term, time-based equity incentive tied to continued service.

How many Pulmonx (LUNG) shares does Geoffrey Beran own after these transactions?

After completing the March 2, 2026 trades and the new award, Geoffrey Beran directly holds 465,734 Pulmonx common shares. This figure reflects both the 7,732 shares sold to cover taxes and the 100,000-share restricted stock unit grant added to his reported direct ownership.

What types of transactions were recorded in this Pulmonx (LUNG) Form 4?

The Form 4 shows four open-market sales of common stock, all coded as “S” and described as sales to cover tax withholding, plus one transaction coded “A” representing a grant or award of restricted stock units, which is classified as an acquisition of derivative equity.